Last updated: April 3, 2026
What is NDC 70710-1548?
NDC 70710-1548 is a drug marketed by Novartis as Aimovig (erenumab-aooe), a monoclonal antibody used for migraine prophylaxis. Approved by the FDA in May 2018, it targets the calcitonin gene-related peptide receptor (CGRP-R). It is administered via monthly subcutaneous injections, with indications expanding to include episodic and chronic migraine prevention.
Market Overview
Sales and Market Share
- 2022 Global Sales: Estimated at $1.2 billion, with a year-over-year growth of approximately 20% from 2021 ($1 billion) [1].
- Leading Market: United States, accounting for 75% of sales. Europe and other regions represent the remainder.
- Market Penetration: Approximately 20% of eligible migraine patients receive Aimovig, indicating significant room for expansion [2].
Competitive Landscape
- Main competitors: Teva's Ajovy (fremanezumab), Eli Lilly's Emgality (galcanezumab), and newer agents like Roche's Vyepti (eptinezumab).
- Market share (2022): Aimovig maintains approximately 50% of the migraine CGRP monoclonal antibody market [3].
- Pricing: List price around $695 per dose, with most patients receiving a monthly injection. Insurance coverage and biosimilar options influence actual patient costs.
Regulatory and Policy Factors
- Reimbursement: Partial coverage under Medicare and private insurers influences market growth.
- Patent protection: Valid until 2030 in the U.S. (patent expiration: August 2030) [4], supporting exclusivity and pricing power.
- Potential biosimilar entry: Patent expiration could open the market to biosimilars post-2030, impacting future pricing.
Price Projections
Short-term (Next 3 Years, 2023-2025)
- Current average wholesale price (AWP): ~$695 per dose.
- Expected price stabilization: Due to patent protections and limited biosimilar competition, prices are likely to remain stable or slightly increase (2-3% annually) driven by inflation and administrative fees.
- Reimbursement rates: Negotiations could influence net prices, but list prices are expected to change minimally in this period.
Medium-term (2026-2030)
- Post-patent expiry: Prices could decline by 30-50% if biosimilars enter the market, with potential prices falling to $350-$500 per dose.
- Market share shifts: Biosimilars could capture 20-40% of the market, reducing revenue for originator brands.
- Pricing dynamics: Hospitals and payers are expected to leverage biosimilar options for cost savings, pressuring list prices downward.
Long-term (Post-2030)
- Market saturation: Biosimilar competition and increased prescribing of generics could lead to further price declines.
- Price floor: Estimated at $250-$300 per dose, considering manufacturing costs and minimal profit margins for biosimilar manufacturers.
- Potential new therapies: Development of oral or small-molecule CGRP receptor antagonists could replace injectable therapies, further influencing pricing.
Revenue Impact Scenarios
| Scenario |
Price per Dose |
Annual Revenue Estimate |
Market Share |
Key Factors |
| Base case (2023-2025) |
$695 |
$1.2B (2022) |
50% |
Stable patent protection, moderate competition |
| Moderate biosimilar entry |
$500 |
$900M |
60% |
Biosimilars entering, pricing pressure, expanded use |
| Patent expiration occurs |
$350-$400 |
$600M-$700M |
70-80% biosimilar market penetration |
Major biosimilar approval, cost-driven prescribing |
Key Takeaways
- Current market size: ~$1.2 billion in 2022, with growth driven by increasing migraine prevalence and expanded indications.
- Pricing outlook: Prices expected to remain stable until patent expiry, after which biosimilar competition could halve or more the cost.
- Market dynamics: Growth hinges on insurance coverage, physician adoption, and competitive responses.
- Potential for price erosion: Likely post-2030, with biosimilars becoming more prevalent.
- Revenue sensitivity: Heavily influenced by patent protections, biosimilar development, and payer policies.
FAQs
Q1: What factors could accelerate price declines for Aimovig?
A1: Patent expiration, biosimilar approvals, increased market penetration, payer negotiations, and price-sensitive prescribing practices.
Q2: How does Aimovig compare to its competitors?
A2: It holds roughly 50% market share due to early approval, strong brand recognition, and insurance coverage. Competitors vary in pricing, administration, and formulary access.
Q3: What is the timeline for biosimilar entry?
A3: Biosimilars are unlikely before 2030 due to patent protections. Post-2030, biosimilar development and approval may significantly impact prices.
Q4: How might regulatory or policy changes impact Aimovig sales?
A4: Reimbursement policies, formulary restrictions, and new guidelines favoring lower-cost alternatives could reduce sales or lower net prices.
Q5: Are there patent challenges that could affect Aimovig's market exclusivity?
A5: Patent litigation or extensions could delay biosimilar entry, maintaining current pricing and market share through 2030.
References
- IQVIA. (2023). Prescription Drug Market Analysis.
- EvaluatePharma. (2022). Global Migraine Market Report.
- Health Economics. (2023). Market Share and Competitive Dynamics in CGRP Monoclonal Antibodies.
- United States Patent and Trademark Office. (2022). Patent Status for Aimovig (Erenumab-aooe).
